Edgewise Therapeutics, Inc.
EWTX
$44.17
$0.992.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.57% | -7.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.47% | -3.33% | |||
| Operating Income | -14.47% | 3.33% | |||
| Income Before Tax | -16.96% | 2.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.96% | 2.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.96% | 2.40% | |||
| EBIT | -14.47% | 3.33% | |||
| EBITDA | -14.60% | 3.38% | |||
| EPS Basic | -16.35% | 3.40% | |||
| Normalized Basic EPS | -16.36% | 3.41% | |||
| EPS Diluted | -16.35% | 3.40% | |||
| Normalized Diluted EPS | -16.36% | 3.41% | |||
| Average Basic Shares Outstanding | 0.52% | 1.04% | |||
| Average Diluted Shares Outstanding | 0.52% | 1.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||